Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1573-7217
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer ; volume:189 ; number:1 ; day:4 ; month:5 ; year:2021 ; pages:213-224 ; date:8.2021
Breast cancer research and treatment ; 189, Heft 1 (4.5.2021), 213-224, 8.2021

Urheber
Groen, Emma J.
Noordaa, Marieke E. M. van der
Schaapveld, Michael
Sonke, Gabe S.
Mann, Ritse M.
Ramshorst, Mette S. van
Lips, Esther H.
Vrancken Peeters, Marie-Jeanne T. F. D.
Duijnhoven, Frederieke H. van
Wesseling, Jelle
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s10549-021-06235-2
URN
urn:nbn:de:101:1-2021102400280344568401
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:35 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Groen, Emma J.
  • Noordaa, Marieke E. M. van der
  • Schaapveld, Michael
  • Sonke, Gabe S.
  • Mann, Ritse M.
  • Ramshorst, Mette S. van
  • Lips, Esther H.
  • Vrancken Peeters, Marie-Jeanne T. F. D.
  • Duijnhoven, Frederieke H. van
  • Wesseling, Jelle
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis

Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis

Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer

Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer

Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism

Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism

In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment

In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment

Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?

PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report

Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer

Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade

Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study

Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Verbundene Objekte